--- title: "Alector (ALEC) news: offering" url: "https://aibio.space/companies/alector/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ALEC offering news: Alector prices $75,030,000 stock offering at $2.05, above prior close. Alector, Inc. (NASDAQ: ALEC), United States." --- ALEC Alector, Inc. NASDAQ · United States # Alector (ALEC) news ALEC offering news Financings · 2026-10-16 ## [Alector prices $75,030,000 stock offering at $2.05, above prior close](https://aibio.space/news/alector-prices-75-030-000-stock-offering-2-05-above-prior-close/) Alector priced 36,600,000 shares at $2.05 for $75,030,000 gross. Its 2025 revenue fell to $21.0 million and cash used in operations was $184.0 million, against $59.9 million of cash on June 30, 2026. ## Latest Alector news 1. 2025-10-21 Distress [Alector cuts workforce by about 49% after latozinemab Phase 3 trial misses endpoint](https://aibio.space/news/alector-cuts-workforce-about-49-percent-after-latozinemab-phase-3/) Alector expects $7.7 million in restructuring charges and reports a preliminary $291.1 million in cash and short-term investments at September 30, 2025. Its head of research and development is resigning. 2. 2025-03-10 Distress [Alector to cut workforce by approximately 13%, expects $2.4 million in restructuring charges](https://aibio.space/news/alector-cut-workforce-approximately-13-percent-expects-2-4-million/) The company says the cut affects about 25 employees and will cost about $2.4 million. It still says cash lasts through 2026, while its lead frontotemporal dementia trial has yet to report and its term loan is secured on substantially all assets. ## Alector at a glance - **Ticker**: ALEC - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $172.8 million ### Related companies - [Aptevo Therapeutics](https://aibio.space/companies/aptevo-therapeutics/) NASDAQ: APVO - [Marker Therapeutics](https://aibio.space/companies/marker-therapeutics/) NASDAQ: MRKR - [Aridis Pharmaceuticals](https://aibio.space/companies/aridis-pharmaceuticals/) OTC: ARDS - [Altimmune](https://aibio.space/companies/altimmune/) NASDAQ: ALT - [ALX Oncology Holdings](https://aibio.space/companies/alx-oncology/) NASDAQ: ALXO - [Carisma Therapeutics](https://aibio.space/companies/carisma-therapeutics/) OTC: CARM - [Vera Therapeutics](https://aibio.space/companies/vera-therapeutics/) NASDAQ: VERA - [ThermoGenesis Holdings](https://aibio.space/companies/thermogenesis/) OTC: THMO ### Also on NASDAQ - [ICON](https://aibio.space/companies/icon/) ICLR - [Latigo Biotherapeutics](https://aibio.space/companies/latigo-biotherapeutics/) LTGO - [Fractyl Health](https://aibio.space/companies/fractyl-health/) GUTS - [Unicycive Therapeutics](https://aibio.space/companies/unicycive-therapeutics/) UNCY - [Aldeyra Therapeutics](https://aibio.space/companies/aldeyra-therapeutics/) ALDX - [Tenon Medical](https://aibio.space/companies/tenon-medical/) TNON ## What Alector does Alector is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases. Its work is informed by disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption. A key component of its strategy is the Alector Brain Carrier platform, a proprietary blood-brain barrier delivery technology designed to improve central nervous system exposure to antibodies, enzymes and siRNA therapeutics at clinically practical doses. Its portfolio includes nivisnebart, formerly AL101 or GSK4527226, an investigational progranulin-elevating antibody. The company is also investing in biomarkers and biomarker assays to guide patient selection, demonstrate target and pathway engagement, and assess biological impact in the clinic. Its programs focus on genetically validated targets, supported by expertise in drug development, protein engineering and antibody discovery. The company says it relies on third parties to conduct clinical trials and to manufacture its product candidates. | Product or program | What it is | Stage | |---|---|---| | Nivisnebart (formerly AL101 or GSK4527226) | Investigational progranulin-elevating antibody for neurodegenerative disease | | | Alector Brain Carrier (ABC) platform | Blood-brain barrier delivery technology for antibodies, enzymes and siRNA | | Summarised from the company's [10-K filed Feb 25, 2026](https://www.sec.gov/Archives/edgar/data/1653087/000119312526071593/alec-20251231.htm). ## Alector annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$21.0 million](https://www.sec.gov/Archives/edgar/data/1653087/000119312526071593/) | [$100.6 million](https://www.sec.gov/Archives/edgar/data/1653087/000119312526071593/) | | Research and development | [$123.1 million](https://www.sec.gov/Archives/edgar/data/1653087/000119312526071593/) | [$185.9 million](https://www.sec.gov/Archives/edgar/data/1653087/000119312526071593/) | | Net income (loss) | [-$142.9 million](https://www.sec.gov/Archives/edgar/data/1653087/000119312526071593/) | [-$119.0 million](https://www.sec.gov/Archives/edgar/data/1653087/000119312526071593/) | | Cash from operations | [-$184.0 million](https://www.sec.gov/Archives/edgar/data/1653087/000119312526071593/) | [-$229.9 million](https://www.sec.gov/Archives/edgar/data/1653087/000119312526071593/) | | Cash and equivalents | [$65.8 million](https://www.sec.gov/Archives/edgar/data/1653087/000119312526338052/) | [$33.0 million](https://www.sec.gov/Archives/edgar/data/1653087/000119312526071593/) | | Short-term investments | [$190.2 million](https://www.sec.gov/Archives/edgar/data/1653087/000119312526338052/) | [$380.4 million](https://www.sec.gov/Archives/edgar/data/1653087/000119312526071593/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $59.9 million, plus short-term investments of $112.9 million, $172.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Alector Has Alector raised money recently? Our latest story on this, dated Oct 16, 2026: "Alector prices $75,030,000 stock offering at $2.05, above prior close". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/alector-prices-75-030-000-stock-offering-2-05-above-prior-close/). What is the ticker symbol of Alector? Alector, Inc. trades under the ticker ALEC on NASDAQ. Where is Alector listed? Alector, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:0Z2; LS:A2PCBM; LSX:A2PCBM. What is the SEC CIK of Alector? The SEC Central Index Key (CIK) for Alector, Inc. is 1653087. Its filings are on SEC EDGAR. How many shares does Alector have outstanding? 111,656,919 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Alector listed under? Our directory records Alector, Inc. under United States. What does Alector do? Our directory classifies Alector, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Alector? The ISIN recorded for Alector, Inc. is US0144421072. Does aibio.space cover Alector? aibio.space lists Alector, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What does Alector develop? Alector is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases. Its work is informed by disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption. What is Nivisnebart (formerly AL101 or GSK4527226) from Alector? Nivisnebart (formerly AL101 or GSK4527226): Investigational progranulin-elevating antibody for neurodegenerative disease What is Alector Brain Carrier (ABC) platform from Alector? Alector Brain Carrier (ABC) platform: Blood-brain barrier delivery technology for antibodies, enzymes and siRNA What was Alector's revenue last year? $21.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Alector profitable? Alector, Inc. reported a net loss of $142.9 million for the fiscal year ended Dec 31, 2025, and used $184.0 million of cash in operations, per its annual report to the SEC. How much does Alector spend on research and development? $123.1 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Alector Members talk about Alector (ALEC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Alector, newest first. Each line links the filing it comes from. 1. 2026-10-16 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1653087/000119312526424204/d417912dex991.htm) 2. 2026-07-08 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1653087/000119312526298526/alec-20260706.htm) 3. 2026-05-07 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1653087/000119312526212417/d66073d424b5.htm) 4. 2025-10-21 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1653087/000119312525245102/alec-ex99_1.htm) 5. 2025-03-10 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). [Source](https://www.sec.gov/Archives/edgar/data/1653087/000119312525050448/d890669d8k.htm) 6. 2024-11-25 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1653087/000095017024130564/alec-ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ALEC on TradingView](https://www.tradingview.com/symbols/NASDAQ-ALEC/). ## SEC filings and registration - **SEC name**: Alector, Inc. - **CIK**: 1653087 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: ALEC (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer
Smaller reporting company - **Business address**: 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: 415-231-5660 - **Shares outstanding**: 111,656,919 as of 2026-07-31 (10-Q filed 2026-08-06) - **Former names**: Alector LLC ### Recent filings (8-K and 6-K are the company's own announcements) - [424B5](https://www.sec.gov/Archives/edgar/data/1653087/000119312526424215/d417628d424b5.htm) filed 2026-10-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1653087/000119312526424204/d417912d8k.htm) filed 2026-10-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1653087/000119312526421080/alec-20261013.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1653087/000119312526413090/alec-20260930.htm) filed 2026-10-05 - [10-Q](https://www.sec.gov/Archives/edgar/data/1653087/000119312526338052/alec-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1653087/000119312526338008/alec-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1653087/000119312526298526/alec-20260706.htm) filed 2026-07-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1653087/000119312526274130/alec-20260617.htm) filed 2026-06-17 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001653087), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Alector, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ALEC, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Alector, Inc. - **Ticker**: ALEC - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US0144421072 - **Other listed symbols**: GETTEX:0Z2; LS:A2PCBM; LSX:A2PCBM - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ALEC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/alector/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Alector (ALEC) news: offering", 2026-10-31, https://aibio.space/companies/alector/